Opinion|Videos|April 18, 2025

Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream

James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.

Episodes in this series

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

  • Where do you see the biggest gap in the current treatment paradigm for pediatric AD, and how might ruxolitinib cream help fill that gap?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME